Bausch Health Companies develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology and dermatology, a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical aesthetic devices and, through its majority ownership of Bausch + Lomb Corporation (Bausch + Lomb), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. Co.'s portfolio of products falls into five operating and reportable segments: Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The BHC YTD return is shown above.
The YTD Return on the BHC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BHC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BHC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|